Event Profile

Go Back

This Webinar will highlight several approaches that have proven effective to overcome obviousness challenges for biologic drug patents, and will include USPTO and practitioner perspectives and recommendations for how to handle obviousness rejections for antibody and other biologic technologies. Immunotherapeutic biologics, including antibodies and cell-based therapies of increasing complexity, are at the forefront of advanced therapies for cancer, Alzheimer’s Disease, and rheumatoid arthritis.  With patents to biologics subject to frequent patentability rejections and challenges during prosecution and in PTAB proceedings, and findings of obviousness being common, this webinar will give the audience an oppor...